Cargando…
Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers all over the world. Several studies have explored if immune-related genes and tumor immune microenvironment could play roles in HCC prognoses. This study is aimed at developing a prognostic signature of HCC based on immune-related gene...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695881/ https://www.ncbi.nlm.nih.gov/pubmed/33246289 http://dx.doi.org/10.1016/j.tranon.2020.100957 |
_version_ | 1783615283992199168 |
---|---|
author | Xu, Ying Wang, Zheng Li, Fufeng |
author_facet | Xu, Ying Wang, Zheng Li, Fufeng |
author_sort | Xu, Ying |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is one of the most common cancers all over the world. Several studies have explored if immune-related genes and tumor immune microenvironment could play roles in HCC prognoses. This study is aimed at developing a prognostic signature of HCC based on immune-related genes or tumor immune microenvironment to predict survival and response to immune checkpoint inhibitors (ICIs). We constructed a prognostic signature using bioinformatics method and validated its predictive capability. The mechanisms of the signature prediction were explored with The Cancer Immunome Atlas (TCIA) and mutation analysis. We also explored the association between the signature and immunophenoscore (IPS), which is the marker of ICIs response. A 6 immune-related-gene (6-IRG) signature was developed. It was revealed in a multivariate analysis that the 6-IRG signature was an independent prognostic factor of overall survival and progression-free interval among HCC patients. In the high-risk group of 6-IRG signature score, macrophage M0 cells and regulatory T cells, which are observed associated with poor overall survival in our study, were higher. The low-risk group had a higher IPS, which meant a better response to ICIs. Taken together, we constructed a reliable 6-IRG signature for prediction of survival and response to ICIs. The signature needs further testing for clinical application. |
format | Online Article Text |
id | pubmed-7695881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76958812020-12-09 Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma Xu, Ying Wang, Zheng Li, Fufeng Transl Oncol Original article Hepatocellular carcinoma (HCC) is one of the most common cancers all over the world. Several studies have explored if immune-related genes and tumor immune microenvironment could play roles in HCC prognoses. This study is aimed at developing a prognostic signature of HCC based on immune-related genes or tumor immune microenvironment to predict survival and response to immune checkpoint inhibitors (ICIs). We constructed a prognostic signature using bioinformatics method and validated its predictive capability. The mechanisms of the signature prediction were explored with The Cancer Immunome Atlas (TCIA) and mutation analysis. We also explored the association between the signature and immunophenoscore (IPS), which is the marker of ICIs response. A 6 immune-related-gene (6-IRG) signature was developed. It was revealed in a multivariate analysis that the 6-IRG signature was an independent prognostic factor of overall survival and progression-free interval among HCC patients. In the high-risk group of 6-IRG signature score, macrophage M0 cells and regulatory T cells, which are observed associated with poor overall survival in our study, were higher. The low-risk group had a higher IPS, which meant a better response to ICIs. Taken together, we constructed a reliable 6-IRG signature for prediction of survival and response to ICIs. The signature needs further testing for clinical application. Neoplasia Press 2020-11-24 /pmc/articles/PMC7695881/ /pubmed/33246289 http://dx.doi.org/10.1016/j.tranon.2020.100957 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Xu, Ying Wang, Zheng Li, Fufeng Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title | Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title_full | Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title_fullStr | Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title_full_unstemmed | Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title_short | Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma |
title_sort | survival prediction and response to immune checkpoint inhibitors: a prognostic immune signature for hepatocellular carcinoma |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695881/ https://www.ncbi.nlm.nih.gov/pubmed/33246289 http://dx.doi.org/10.1016/j.tranon.2020.100957 |
work_keys_str_mv | AT xuying survivalpredictionandresponsetoimmunecheckpointinhibitorsaprognosticimmunesignatureforhepatocellularcarcinoma AT wangzheng survivalpredictionandresponsetoimmunecheckpointinhibitorsaprognosticimmunesignatureforhepatocellularcarcinoma AT lifufeng survivalpredictionandresponsetoimmunecheckpointinhibitorsaprognosticimmunesignatureforhepatocellularcarcinoma |